Pharma Pfizer, in an attempt to bolster its oncology portfolio, is set to acquire Array Biopharma for USD 10.6 billion in the second half of 2019. The deal will give Pfizer access to Array’s cancer treatments which are showing promise in phase III trials and protect it against the looming patent…
See our Cookie Privacy Policy Here